Liu Yongzhen, Park Debby, Cafiero Thomas R, Bram Yaron, Chandar Vasuretha, Tseng Anna, Gertje Hans P, Crossland Nicholas A, Su Lishan, Schwartz Robert E, Ploss Alexander
Department of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Princeton, NJ, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
JHEP Rep. 2022 Jul 9;4(9):100535. doi: 10.1016/j.jhepr.2022.100535. eCollection 2022 Sep.
BACKGROUND & AIMS: HBV exhibits wide genetic diversity with at least 9 genotypes (GTs), which differ in terms of prevalence, geographic distribution, natural history, disease progression, and treatment outcome. However, differences in HBV replicative capacity, gene expression, and infective capability across different GTs remain incompletely understood. Herein, we aimed to study these crucial aspects using newly constructed infectious clones covering the major HBV GTs.
The replicative capacity of infectious clones covering HBV GTs A-E was analyzed in cell lines, primary hepatocytes and humanized mice. Host responses and histopathology induced by the different HBV GTs were characterized in hydrodynamically injected mice. Differences in treatment responses to entecavir and various HBV capsid inhibitors were also quantified across the different genetically defined GTs.
Patient-derived HBV infectious clones replicated robustly both and . GTs A and D induce more pronounced intrahepatic and proinflammatory cytokine responses which correlated with faster viral clearance. Notably, all 5 HBV clones robustly produced viral particles following transfection into HepG2 cells, and these particles were infectious in HepG2-NTCP cells, primary human hepatocytes and human chimeric mice. Notably, GT D virus exhibited higher infectivity than GTs A, B, C and E , although it was comparable to GT A and B in the human liver chimeric mice . HBV capsid inhibitors were more readily capable of suppressing HBV GTs A, B, D and E than C.
The infectious clones described here have broad utility as genetic tools that can mechanistically dissect intergenotypic differences in antiviral immunity and pathogenesis and aid in HBV drug development and screening.
The hepatitis B virus (HBV) is a major contributor to human morbidity and mortality. HBV can be categorized into a number of genotypes, based on their specific genetic make-up, of which 9 are well known. We isolated and cloned the genomes of 5 of these genotypes and used them to create valuable tools for future research on this clinically important virus.
乙肝病毒(HBV)呈现出广泛的基因多样性,至少有9种基因型(GTs),它们在流行率、地理分布、自然史、疾病进展和治疗结果方面存在差异。然而,不同GTs之间HBV复制能力、基因表达和感染能力的差异仍未完全了解。在此,我们旨在使用涵盖主要HBV GTs的新构建感染性克隆来研究这些关键方面。
在细胞系、原代肝细胞和人源化小鼠中分析涵盖HBV GTs A-E的感染性克隆的复制能力。在经 hydrodynamic 注射的小鼠中表征不同HBV GTs诱导的宿主反应和组织病理学。还对不同基因定义的GTs对恩替卡韦和各种HBV衣壳抑制剂的治疗反应差异进行了量化。
患者来源的HBV感染性克隆在[具体情况1]和[具体情况2]中均能强劲复制。GTs A和D诱导更明显的肝内和促炎细胞因子反应,这与更快的病毒清除相关。值得注意的是,所有5种HBV克隆转染到HepG2细胞后均能强劲产生病毒颗粒,并且这些颗粒在HepG2-NTCP细胞、原代人肝细胞和人嵌合小鼠中具有感染性。值得注意的是,GT D病毒的感染性高于GTs A、B、C和E[具体情况3],尽管在人肝嵌合小鼠中它与GT A和B相当[具体情况4]。HBV衣壳抑制剂比C更易于抑制HBV GTs A、B、D和E。
本文所述的感染性克隆作为遗传工具具有广泛用途,可从机制上剖析抗病毒免疫和发病机制中的基因型间差异,并有助于HBV药物开发和筛选。
乙肝病毒(HBV)是导致人类发病和死亡的主要因素。根据其特定的基因组成,HBV可分为多种基因型,其中9种是众所周知的。我们分离并克隆了其中5种基因型的基因组,并将其用于为未来对这种临床重要病毒的研究创建有价值的工具。